Related references
Note: Only part of the references are listed.Structural and Chemical Biology of Presenilin Complexes
Douglas S. Johnson et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS
Janis-Bennion Callister et al.
EXPERIMENTAL NEUROLOGY (2014)
Neuronal activity regulates extracellular tau in vivo
Kaoru Yamada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles
Diana L. Castillo-Carranza et al.
JOURNAL OF NEUROSCIENCE (2014)
Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
David W. Sanders et al.
NEURON (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lost after translation: missorting of Tau protein and consequences for Alzheimer disease
Hans Zempell et al.
TRENDS IN NEUROSCIENCES (2014)
Amyloid-Beta Oligomerization in Alzheimer Dementia versus High-Pathology Controls
Thomas J. Esparza et al.
ANNALS OF NEUROLOGY (2013)
Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease
Aaron H. Burstein et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study
Jaren W. Landen et al.
CLINICAL NEUROPHARMACOLOGY (2013)
Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy
Michiyo Iba et al.
JOURNAL OF NEUROSCIENCE (2013)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Victor L. Villemagne et al.
LANCET NEUROLOGY (2013)
Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo
Kiran Yanamandra et al.
NEURON (2013)
Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease
Martin Farlow et al.
ALZHEIMERS & DEMENTIA (2012)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease
Sherry L. La Porte et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Developing ß-secretase inhibitors for treatment of Alzheimer's disease
Arun K. Ghosh et al.
JOURNAL OF NEUROCHEMISTRY (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad et al.
LANCET NEUROLOGY (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
Alix de Calignon et al.
NEURON (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trans-Synaptic Spread of Tau Pathology In Vivo
Li Liu et al.
PLOS ONE (2012)
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
Cristian A. Lasagna-Reeves et al.
SCIENTIFIC REPORTS (2012)
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models REDUCTION OF TAU PATHOLOGY AND DELAY OF DISEASE PROGRESSION
Xiyun Chai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Jing L. Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
Allal Boutajangout et al.
JOURNAL OF NEUROCHEMISTRY (2011)
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner et al.
JOURNAL OF NEUROSCIENCE (2011)
In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice
Kaoru Yamada et al.
JOURNAL OF NEUROSCIENCE (2011)
Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice
Mian Bi et al.
PLOS ONE (2011)
Alzheimer's Disease: The Challenge of the Second Century
David M. Holtzman et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease
Delphine Boche et al.
ACTA NEUROPATHOLOGICA (2010)
Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology
Alberto Serrano-Pozo et al.
BRAIN (2010)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid beta After a Single Administration of an Amyloid beta Monoclonal Antibody in Subjects With Alzheimer Disease
Eric R. Siemers et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Allal Boutajangout et al.
JOURNAL OF NEUROSCIENCE (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Bess Frost et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
DEVELOPMENT OF AFFITOPE VACCINES FOR ALZHEIMER'S DISEASE (AD) - FROM CONCEPT TO CLINICAL TESTING
A. Schneeberger et al.
JOURNAL OF NUTRITION HEALTH & AGING (2009)
Transmission and spreading of tauopathy in transgenic mouse brain
Florence Clavaguera et al.
NATURE CELL BIOLOGY (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Active and passive immunotherapy for Neurodegenerative disorders
David L. Brody et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Alzheimer's disease - Moving towards a vaccine
David M. Holtzman
NATURE (2008)
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Ganesh M. Shankar et al.
NATURE MEDICINE (2008)
Experimental investigation of antibody-mediated clearance mechanisms of amyloid-β in CNS of Tg-SwDI transgenic mice
Vitaly Vasilevko et al.
JOURNAL OF NEUROSCIENCE (2007)
Clearance of amyloid-β by circulating lipoprotein receptors
Abhay Sagare et al.
NATURE MEDICINE (2007)
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements
Ayodeji A. Asuni et al.
JOURNAL OF NEUROSCIENCE (2007)
Active β-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β-amyloid
Guiquan Chen et al.
JOURNAL OF NEUROSCIENCE (2007)
Reduction of soluble Aβ and Tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles
Salvatore Oddo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease
RE Hartman et al.
JOURNAL OF NEUROSCIENCE (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
E Masliah et al.
NEUROLOGY (2005)
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives
EM Sigurdsson et al.
JOURNAL OF NEUROSCIENCE (2004)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
R Deane et al.
NATURE MEDICINE (2003)
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
C Hock et al.
NEURON (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice
R Furlan et al.
BRAIN (2003)
Cerebral hemorrhage after passive anti-Aβ immunotherapy
M Pfeifer et al.
SCIENCE (2002)
Alzheimer's disease is a synaptic failure
DJ Selkoe
SCIENCE (2002)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
JC Dodart et al.
NATURE NEUROSCIENCE (2002)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
γ-Secretase, notch, Aβ and Alzheimer's disease:: Where do the presenilins fit in?
SS Sisodia et al.
NATURE REVIEWS NEUROSCIENCE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Targeting small Aβ oligomers:: the solution to an Alzheimer's disease conundrum?
WL Klein et al.
TRENDS IN NEUROSCIENCES (2001)
Neurodegenerative tauopathies
VMY Lee et al.
ANNUAL REVIEW OF NEUROSCIENCE (2001)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
C Janus et al.
NATURE (2000)
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
D Morgan et al.
NATURE (2000)
Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
M Shibata et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
J Lewis et al.
NATURE GENETICS (2000)
Share Paper
